ストックスクリーナーアプリを入手
1.83
2.23%
0.04
プレマーケット:
1.85
0.02
+1.09%
前日終値:
$1.79
開ける：
$1.85
24時間の取引高:
810.61K
Relative Volume:
0.91
時価総額：
$259.76M
収益：
$893.00K
当期純損益:
$-151.61M
株価収益率:
-3.552
EPS:
-0.5152
ネットキャッシュフロー:
$-135.31M
1週間 パフォーマンス:
-12.02%
1か月 パフォーマンス:
-19.03%
6か月 パフォーマンス:
-30.15%
1年 パフォーマンス:
+81.19%
1日の値動き範囲:
$1.80
$1.90
1週間の範囲:
$1.78
$2.10
52週間の値動き範囲:
$0.4603
$7.13
Prokidney Corp Stock (PROK) Company Profile
Compare PROK vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PROK
Prokidney Corp
|
1.83 | 254.08M | 893.00K | -151.61M | -135.31M | -0.5152 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-16 | 開始されました | H.C. Wainwright | Buy |
| 2025-06-30 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2024-09-30 | 開始されました | JP Morgan | Neutral |
| 2024-09-10 | 開始されました | Guggenheim | Buy |
| 2024-03-07 | 再開されました | Morgan Stanley | Equal-Weight |
| 2024-01-02 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-07-25 | 開始されました | BTIG Research | Buy |
| 2022-12-21 | 開始されました | Jefferies | Buy |
| 2022-11-10 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-10-18 | 開始されました | UBS | Buy |
| 2022-10-14 | 開始されました | Citigroup | Buy |
| 2022-09-23 | 開始されました | BofA Securities | Buy |
| 2022-09-02 | 開始されました | Evercore ISI | Outperform |
すべてを表示
Prokidney Corp (PROK) 最新ニュース
ProKidney appoints Greg Madison as chief commercial officer - TipRanks
ProKidney names Greg Madison as chief commercial officer - Investing.com
ProKidney names Greg Madison as chief commercial officer By Investing.com - Investing.com UK
Prokidney Corp. Appoints Greg Madison as Chief Commercial Officer - marketscreener.com
ProKidney (NASDAQ:PROK) Trading Down 7.6%Here's What Happened - MarketBeat
Q2 Earnings Forecast for ProKidney Issued By HC Wainwright - MarketBeat
ProKidney Corp. (NASDAQ:PROK) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Insider Sell: Does ProKidney Corp offer margin of safety2026 Outlook & Capital Efficiency Focused Ideas - baoquankhu1.vn
ProKidney (NASDAQ:PROK) Cut to Sell at Wall Street Zen - MarketBeat
ProKidney narrows loss to $150M as it eyes crucial kidney treatment trial results - The Business Journals
Analysts Offer Insights on Healthcare Companies: ProKidney (PROK), Molecular Partners (MOLN) and Bristol-Myers Squibb (BMY) - The Globe and Mail
Equities Analysts Set Expectations for ProKidney Q1 Earnings - MarketBeat
Guggenheim Sticks to Its Buy Rating for ProKidney (PROK) - The Globe and Mail
ProKidney’s Greensboro Facility Could Shield It From Looming Tariff Risks—But Time Is Short - Bitget
Trade Policy Risks: How Evolving U.S. Tariffs and Export Rules Threaten ProKidney Corp.’s Supply Chain and Financial Stability - TipRanks
ProKidney Makes Major Wager on U.S. Tariff Relief—Does Consistent Policy Support a $485M Risk? - Bitget
ProKidney ends fiscal 2025 with bigger loss, larger revenue stream - Winston-Salem Journal
ProKidney: Extended Development Timeline and Deferred Catalysts Support Balanced Hold Rating - TipRanks
ProKidney (NASDAQ:PROK) Raised to "Strong-Buy" at Jefferies Financial Group - MarketBeat
BofA reiterates ProKidney stock Underperform rating at $1 target By Investing.com - Investing.com South Africa
ProKidney Corp. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
BofA reiterates ProKidney stock Underperform rating at $1 target - Investing.com
ProKidney (NASDAQ:PROK) Releases Earnings Results - MarketBeat
ProKidney Reports Full Year 2025 Financial Results and Business Highlights - Bitget
PROK: FDA alignment, strong clinical progress, and cash runway into 2027 despite ongoing losses - TradingView
ProKidney (Nasdaq: PROK) details 2025 loss and cash runway into 2027 - Stock Titan
ProKidney (PROK) advances Phase 3 rilparencel program for diabetic CKD - Stock Titan
ProKidney’s High Cash Usage Dims Pipeline Hopes—Investors Brace for Funding Shortfall Before 2027 Results - Bitget
ETF Watch: How volatile is ProKidney Corp stock2026 PreEarnings & Entry and Exit Point Strategies - baoquankhu1.vn
Aug Update: Why is ProKidney Corp stock going downRisk Management & AI Powered Market Entry Ideas - baoquankhu1.vn
ProKidney (NASDAQ:PROK) Stock Price Down 4.7%Time to Sell? - MarketBeat
Dividend Watch: Is ProKidney Corp stock undervalued right now2026 Update & Real-Time Price Movement Reports - baoquankhu1.vn
ProKidney’s Unclear Messages Leave Traders Puzzled - Bitget
Portfolio Shifts: Is ProKidney Corp impacted by rising ratesOptions Play & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Meet the Biotech Stock That Rocketed 775% Higher - MSN
Prokidney Corp expected to post a loss of 12 cents a shareEarnings Preview - TradingView
Momentum Shift: Is ProKidney Corp stock undervalued right nowWeekly Trade Recap & Reliable Volume Spike Alerts - baoquankhu1.vn
ProKidney (PROK) Projected to Post Earnings on Monday - MarketBeat
ProKidney, FDA align on accelerated approval pathway for Rilparencel - MSN
Can ProKidney Corp. stock hit record highs again2026 Fundamental Recap & Safe Entry Zone Tips - Naître et grandir
Why ProKidney Corp. stock could outperform in 2026Rate Cut & AI Enhanced Trading Alerts - Naître et grandir
Smart Money: Is ProKidney Corp impacted by rising rates2025 AllTime Highs & Breakout Confirmation Trade Signals - baoquankhu1.vn
Wall Street Recap: Does ProKidney Corp offer margin of safetyQuarterly Portfolio Review & Long-Term Safe Investment Ideas - baoquankhu1.vn
ProKidney (NASDAQ:PROK) Stock Price Up 9%Here's Why - MarketBeat
PROKIDNEY CORP. (PROK) CFO awarded 600,000-share stock option grant - Stock Titan
ProKidney (NASDAQ: PROK) awards 400,000 stock options to Chief Regulatory Officer - Stock Titan
ProKidney (PROK) grants CLO Todd Girolamo 600,000 stock options - Stock Titan
ProKidney (NASDAQ: PROK) CEO awarded stock options on 3,000,000 shares - Stock Titan
PROK Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
PROK Should I Buy - Intellectia AI
ProKidney Corp. (NASDAQ:PROK) Given Average Rating of "Hold" by Analysts - MarketBeat
Prokidney Corp (PROK) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):